RARE BIRD FOUNDATION

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2024

Legal Domicile

Principal Officer

NAJAH BHATTY

Phone

8478407678

Tax Period

2025-01-01 to 2025-12-31

RARE BIRD FOUNDATION, founded in 2024, is a small nonprofit in the Diseases & Disorders sector that reported $127K in total revenue in fiscal year 2025. Revenue fell 37% from the prior year — a significant decline worth monitoring. Expenses of $234K exceeded revenue, resulting in a 85% operating deficit.

Mission

Working with our partners worldwide , Rare Bird aims to create the first-ever globally approved drug to tackle the transcription factor Myocyte Enhancer Factor 2C MEF2C deficiency within five years.

Program Service Accomplishments

Program 1

Expenses: $234,141

Our flagship program is the MEF2C Haploinsufficiency Syndrome communitys first ever natural history study and clinical readiness study out of Weill Cornell Medical Center. We paid 231141 to Cornell to pay for one of five milestone payments.The expenses were used by Cornell to pay for clinical staff, research fees, and travel expenses for patients in accordance with the Studys contractual terms.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2025)

Revenue Breakdown

Contributions & Grants $126,861

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $126,861

Expense Breakdown

Grants Paid $234,141

Salaries & Benefits $0

Fundraising Expenses $0

Program Expenses $234,141

Other Expenses $330

TOTAL EXPENSES $234,471

Year-over-Year Comparison

	2025	2024	Change
Revenue	$126,861	$201,500	-0.4%
Expenses	$234,471	$2,849	+81.3%
Net Income	$-107,610	$198,651	-1.5%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
HIBA BHATTY	PRESIDENT	005.00	Officer Director	$0	$0	$0
NOOR OSMAN	VICE PRESIDENT	005.00	Officer Director	$0	$0	$0
NAJAH BHATTY	SECRETARY/TREASURER	003.00	Officer Director	$0	$0	$0
JAMES KELLY	DIRECTOR	010.00	Director	$0	$0	$0
AHMED ELGHAZALY	DIRECTOR	003.00	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$126,861	$234,471	$91,041	$-107,610
2024	$201,500	$2,849	$198,651	$198,651